Clinical trials: active, not recruiting
Digestive System Carcinoma, Genitourinary System Carcinoma
Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery
This phase III trial compares a home-based telemonitoring program that collects symptom and daily step information to surgeon only care in improving recovery and stopping complications within 30 days after surgery in patients…
- Conditions
- Digestive System Carcinoma, Genitourinary System Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04596384
- Testing
- Best Practice, Functional Assessment, Medical Device Usage and Evaluation
- Where
- 3 sites in United States
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, Down Syndrome
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome.
- Conditions
- Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome
- Trial name
- NCT02521493
- Testing
- Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine
- Where
- 191 sites in United States, Australia and 4 more
- Volunteers
- 280 people
- Sponsor
- Children's Oncology Group
Prostate Cancer
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591, that can be given without severe side effects.
- Trial name
- NCT04506567
- Testing
- Multiple Dose of 225Ac-J591 at 45 KBq/kg, Multiple Dose of 225Ac-J591 at 55 KBq/kg, Multiple Dose of 225Ac-J591 at 65 KBq/kg
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
Advanced Breast Cancer, Anxiety
RCT of CBD for Anxiety in Advanced Breast Cancer
This research study is investigating use of a single dose of cannabidiol (CBD) to help manage anticipatory anxiety in participants with advanced breast cancer poised to undergo computed tomography (CT) or positron emission…
- Conditions
- Advanced Breast Cancer, Anxiety, CBD
- Trial name
- NCT04482244
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Locally Advanced or Metastatic Solid Tumours
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT04999969
- Testing
- AZD0171, Durvalumab, Gemcitabine
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to…
- Trial name
- NCT04179032
- Testing
- Belimumab
- Where
- 11 sites in United States, Argentina and 5 more
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Hemophilia A
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
C3731003 is a pivotal Phase 3 study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants…
- Trial name
- AFFINE (NCT04370054)
- Testing
- PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
- Where
- 45 sites in United States, Australia and 14 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Pancreas Cancer
A Supervised Prehabilitation Program for Patients With Pancreatic Cancer
The purpose of this study is to assess the use of an exercise program in people with pancreatic cancer.
- Trial name
- PREHAB (NCT05692323)
- Testing
- PREHAB
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Cedars-Sinai Medical Center
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
This phase II trial studies how well cabozantinib s-malate works in treating patients with osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of improvement.
- Conditions
- Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma
- Trial name
- NCT02243605
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Hairy Cell Leukemia
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for HCL.
- Trial name
- NCT00923013
- Testing
- Cladribine, Rituximab, BMbx
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
HER2-mutant Non-Small Cell Lung Cancer
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
- Trial name
- DL-05 (NCT05246514)
- Testing
- Trastuzumab deruxtecan
- Where
- 28 sites in China
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma.
- Conditions
- Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma
- Trial name
- NCT03198026
- Testing
- Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT03732820
- Testing
- olaparib, abiraterone acetate
- Where
- 132 sites in United States, Australia and 15 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Sickle Cell Disease, Thalassemia
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Background: Some sickle cell disease or beta-thalassemia can be cured with transplant. Researchers want to test a variation of transplant that uses low dose radiation and a combination of immunosuppressive drugs.
- Conditions
- Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT02105766
- Testing
- Alemtuzumab, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diffuse Large B Cell Lymphoma, DLBCL
Split-Dose R-CHOP for Older Adults With DLBCL
This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an…
- Conditions
- Diffuse Large B Cell Lymphoma, DLBCL, Cancer
- Trial name
- NCT03943901
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Wisconsin, Madison
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
This randomized phase II trial studies how well hypofractionated radiation therapy (RT) works compared to standard RT in treating patients with ductal breast carcinoma in situ (DCIS) or early invasive breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v6, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01266642
- Testing
- External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 301 people
- Sponsor
- M.D. Anderson Cancer Center
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Overweight or Obesity
- Trial name
- ATTAIN-1 (NCT05869903)
- Testing
- Orforglipron
- Where
- 138 sites in United States, Brazil and 8 more
- Volunteers
- 3,127 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver.
- Trial name
- NCT04550481
- Testing
- Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Advanced Solid Neoplasms
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of…
- Trial name
- NCT03742895
- Testing
- Olaparib
- Where
- 130 sites in United States, Argentina and 19 more
- Volunteers
- 329 people
- Sponsor
- Merck Sharp & Dohme LLC
Neurofibromatosis Type 1
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints.
- Trial name
- SPRINKLE (NCT05309668)
- Testing
- Selumetinib granule formulation, Selumetinib capsule formulation
- Where
- 16 sites in United States, Germany and 5 more
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.